Lazard Asset Management
MRVI icon

Lazard Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Lazard Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62M Sell
420,360
-427,439
-50% -$1.85M ﹤0.01% 860
2026
Q1 		$2.4M Sell
847,799
-170,919
-17% -$579K ﹤0.01% 812
2025
Q4 		$3.31M Sell
1,018,718
-521,508
-34% -$1.76M 0.01% 683
2025
Q3 		$4.42M Buy
1,540,226
+89,805
+6% +$229K 0.01% 611
2025
Q2 		$3.5M Buy
1,450,421
+44,128
+3% +$92.7K ﹤0.01% 839
2025
Q1 		$3.11M Sell
1,406,293
-41,421
-3% -$164K ﹤0.01% 829
2024
Q4 		$7.89M Buy
1,447,714
+127,672
+10% +$821K 0.01% 526
2024
Q3 		$11M Buy
1,320,042
+169,468
+15% +$1.46M 0.01% 447
2024
Q2 		$8.24M Buy
1,150,574
+785,415
+215% +$6.78M 0.01% 553
2024
Q1 		$3.17M Buy
365,159
+359,411
+6,253% +$2.43M ﹤0.01% 761
2023
Q4 		$37K Buy
5,748
+1,934
+51% +$12.5K ﹤0.01% 1971
2023
Q3 		$37K Buy
3,814
+159
+4% +$1.75K ﹤0.01% 1942
2023
Q2 		$44K Sell
3,655
-5,695
-61% -$76.9K ﹤0.01% 1874
2023
Q1 		$130K Buy
9,350
+6,027
+181% +$86.6K ﹤0.01% 1433
2022
Q4 		$47K Buy
3,323
+3,283
+8,208% +$51.7K ﹤0.01% 1849
2022
Q3 		$1K Sell
40
-61
-60% -$1.53K ﹤0.01% 2259
2022
Q2 		$2K Hold
101
– – ﹤0.01% 2295
2022
Q1 		$3K Sell
101
-211
-68% -$7.07K ﹤0.01% 2220
2021
Q4 		$13K Sell
312
-351,638
-100% -$14.2M ﹤0.01% 2103
2021
Q3 		$17.3M Sell
351,950
-1,366,771
-80% -$66.7M 0.02% 517
2021
Q2 		$71.7M Sell
1,718,721
-1,642,546
-49% -$63.7M 0.08% 215
2021
Q1 		$120M Sell
3,361,267
-54,030
-2% -$1.79M 0.15% 127
2020
Q4 		$95.8M Buy
+3,415,297
New +$95.1M 0.12% 153

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Lazard Asset Management's MRVI Position: Q2 2026 in Review

Lazard Asset Management reduced its Maravai LifeSciences (MRVI) stake by 50% in Q2 2026, selling an estimated $1.85M and leaving 420,360 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #860.

Lazard Asset Management first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $120M in Q1 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Lazard Asset Management held 420,360 shares of Maravai LifeSciences worth $2.62M as of Q2 2026.
  • Lazard Asset Management sold 427,439 Maravai LifeSciences shares in Q2 2026, an estimated $1.85M.
  • Maravai LifeSciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #860 holding.
  • Lazard Asset Management first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • Lazard Asset Management's Maravai LifeSciences position peaked at $120M in Q1 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.